KOSDAQ · 141080 · Biotech & Pharma · ₩141080

LigaChem Biosciences리가켐바이오

141080 · KOSDAQ · ₩141080 · 리가켐바이오

₩64,000▼ ₩2,200 (3.32%)End-of-day · Oct 29, 2026 · End-of-day prices.

Trade

Sell Buy

Filings

5%+ holding report주식등의대량보유상황보고서(약식)Oct 2, 2026Open on DART
Major management matter relevant to investors투자판단관련주요경영사항 (iADC 플랫폼 공동연구 및 기술도입 계약 체결)Sep 30, 2026Open on DART
Investor relations (IR) event기업설명회(IR)개최Sep 8, 2026Open on DART
Disclosure on Large Business Group Status [Quarterly Disclosure (For Individual Company)]대규모기업집단현황공시[분기별공시(개별회사용)]Aug 31, 2026Open on DART
Half-year report (Jun 2026)반기보고서 (2026.06)Aug 14, 2026Open on DART
Matters Concerning Payment Amounts by Payment Method and Payment Period, and Dispute Mediation Bodies지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항Aug 14, 2026Open on DART
Major management matter relevant to investors투자판단관련주요경영사항 (LNCB74(B7H4-ADC) 단독 개발 및 기술이전 권리 확보)Aug 7, 2026Open on DART
5%+ holding report주식등의대량보유상황보고서(일반)Aug 4, 2026Open on DART
Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Aug 4, 2026Open on DART
5%+ holding report주식등의대량보유상황보고서(일반)Aug 4, 2026Open on DART
5%+ holding report주식등의대량보유상황보고서(약식)Jul 31, 2026Open on DART
Securities Issuance Results (Voluntary Disclosure)증권발행결과(자율공시)Jul 24, 2026Open on DART
Securities Issuance Results (Voluntary Disclosure)증권발행결과(자율공시)Jul 24, 2026Open on DART
Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jul 24, 2026Open on DART
5%+ holding report주식등의대량보유상황보고서(일반)Jul 24, 2026Open on DART
Amended: Rights offering (paid-in capital increase) decision[기재정정]주요사항보고서(유상증자결정)Jul 22, 2026Open on DART
Amended: Convertible bond issue decision[기재정정]주요사항보고서(전환사채권발행결정)Jul 22, 2026Open on DART
Amended: Convertible bond issue decision[기재정정]주요사항보고서(전환사채권발행결정)Jul 16, 2026Open on DART
Amended: Rights offering (paid-in capital increase) decision[기재정정]주요사항보고서(유상증자결정)Jul 16, 2026Open on DART
Major management matter relevant to investors투자판단관련주요경영사항 (LCB97 관련 마일스톤 기술료 수령)Jul 9, 2026Open on DART
Investor relations (IR) event기업설명회(IR)개최Jun 30, 2026Open on DART
Rights offering (paid-in capital increase) decision주요사항보고서(유상증자결정)Jun 26, 2026Open on DART
Convertible bond issue decision주요사항보고서(전환사채권발행결정)Jun 26, 2026Open on DART
Disclosure of Large Business Group Status [Annual Disclosure and Q1 Use (Individual Companies)]대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]Jun 1, 2026Open on DART
Quarterly report (Mar 2026)분기보고서 (2026.03)May 15, 2026Open on DART
Amended: Investor relations (IR) event[기재정정]기업설명회(IR)개최May 14, 2026Open on DART
Investor relations (IR) event기업설명회(IR)개최May 14, 2026Open on DART
Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획승인신청등결정) (CLDN18.2 항체-약물 접합체 (ADC) LCB02A의 제 1/2상 임상시험의 미국 임상시험계획(IND) 승인)May 14, 2026Open on DART
Change of CEO대표이사변경Apr 29, 2026Open on DART
Change of CEO수시공시의무관련사항(공정공시) (대표이사 변경 예정)Apr 28, 2026Open on DART
Major management matter relevant to investors투자판단관련주요경영사항(임상시험계획승인신청) (CLDN18.2 항체-약물 접합체 (ADC) LCB02A의 제 1/2상 임상시험의 미국 임상시험계획(IND) 승인 신청)Apr 14, 2026Open on DART
Exercise of Stock Purchase Options주식매수선택권행사Apr 8, 2026Open on DART
Major management matter relevant to investors투자판단관련주요경영사항 (신규 기전 신약 연구개발을 위한 기술도입 계약 체결)Apr 6, 2026Open on DART
Major management matter relevant to investors투자판단관련주요경영사항 (신규 항체-약물 결합체(ADC) 연구개발을 위한 공동연구 및 항체 기술도입 계약 해지)Apr 2, 2026Open on DART
Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Apr 1, 2026Open on DART
5%+ holding report주식등의대량보유상황보고서(일반)Apr 1, 2026Open on DART
Annual general meeting results정기주주총회결과Mar 31, 2026Open on DART
Notice on Grant of Stock Purchase Options주식매수선택권부여에관한신고Mar 31, 2026Open on DART
Investor relations (IR) event기업설명회(IR)개최Mar 25, 2026Open on DART
Trust Contract Termination Result Report신탁계약해지결과보고서Mar 25, 2026Open on DART
Audit report submitted감사보고서제출Mar 23, 2026Open on DART
Annual report (Dec 2025)사업보고서 (2025.12)Mar 23, 2026Open on DART
Reference Document for Proxy Solicitation of Voting Rights의결권대리행사권유참고서류Mar 13, 2026Open on DART
Notice of shareholders' meeting주주총회소집공고Mar 13, 2026Open on DART
Shareholders' meeting called주주총회소집결의Mar 10, 2026Open on DART
Major management matter relevant to investors투자판단관련주요경영사항 (신규 항체약물 결합체(ADC) 연구개발을 위한 항체 기술도입 계약 체결 )Feb 24, 2026Open on DART
Change in Revenue or Profit/Loss Structure of 30% or More (15% or More for Large Companies)매출액또는손익구조30%(대규모법인은15%)이상변동Feb 13, 2026Open on DART
Determination of Shareholder Register Closure Period or Record Date주주명부폐쇄기간또는기준일설정Dec 16, 2025Open on DART
Quarterly report (Sep 2025)분기보고서 (2025.09)Nov 14, 2025Open on DART
Report on Results of Disposal of Treasury Shares자기주식처분결과보고서Oct 2, 2025Open on DART

Titles in Korean until English translations are added.

Also known as: LigaChem Biosciences / 리가켐바이오 / 141080 / KRX:141080

Source: KRX statistical information